

There's a lot riding on your prostate test...

KNOW THE SCORE.



Want to know your risk for aggressive prostate cancer?

ClarityDX Prostate can help!

What is ClarityDX Prostate?

ClarityDX Prostate is a blood test that gives you and your doctor more information about whether to have a prostate biopsy done or not. ClarityDX Prostate is up to 3X more accurate than PSA for predicting aggressive prostate cancer⁽¹⁻⁶⁾.



The result of the ClarityDX Prostate test indicates your relative risk of finding aggressive prostate cancer if an invasive biopsy is performed.



For more information about the benefits of the ClarityDX Prostate test please go to

www.nanosticsdx.com
or email: info@nanosticsdx.com



Test performed by Nanostics Clinical Lab CPSA Accreditation Facility No. L0526000. 10133-103 Street NW, APL, Suite 4 TRC, Edmonton, AB, T5J 5E2.



A Simple Test Bringing Clarity to

Prostate Cancer Screening

How Much Does the ClarityDX Prostate Test Cost? ClarityDX Prostate is currently available as a private pay test and is not covered by Alberta Health. It may be eligible for reimbursement through your employer's health spending account. For cost information please go to www.nanosticsdx.com/claritydx-prostate or scan the OR code.





What Can PSA Tell You?

The PSA test measures the level of prostate specific antigen in your blood. High levels of blood PSA can indicate the presence of cancer in the prostate. However, there are many reasons why you might have a high PSA level that have no relation to cancer. In fact, only 1 in 4 men with high PSA levels have prostate cancer. PSA testing also finds indolent prostate cancer that may not need treatment leading to men opting for unnecessary treatments with potential harmful side effects^(7,8).

ClarityDX Prostate is designed for men with elevated PSA levels to help identify men with aggressive prostate cancer.



What is Indolent vs. Aggressive Prostate Cancer?

Indolent prostate cancer is low-risk because the cancer stays in the prostate. The five year survival rate for indolent prostate cancer is 98-100%. Aggressive prostate cancer is high-risk because it spreads from the prostate and forms cancerous tumors at distant site(s) in the body.

The five year survival rate drops to 32% for men with aggressive prostate cancer^(7,8).



Prostate Cancer screening

The Canadian Urology Association (CUA) suggests having a discussion with your doctor about whether PSA screening and alternative tests are right for you⁽⁷⁾.



Get Clarity on Your Prostate Health

ClarityDX Prostate gives you and your doctor more information about what your elevated PSA levels mean and whether to have a prostate biopsy done or continue monitoring PSA levels instead.

Patients with PSA levels of 3 ng/ml or higher and without a prior diagnosis of prostate cancer are eligible for the ClarityDX Prostate test.

References

- 1) Hyndman et al. (2024). npj Digital Medicine 7, 163.
- 2) Wallis et al. (2024) JCO 42, e17105-e17105.
- 3) Hyndman et al. (2024). Can Urol Assoc J 18 (6Suppl).
- 4) Wallis et al. (2023)JCO 41, 5023-5023.
- 5) Paproski et al. (2023). Eur Urol 83, S91-S92.
- 6) Paproski et al. (2023). Can Urol Assoc J. 17 ((6 Suppl 2)
- 7) Mason et al. 2022. Can Urol Assoc J. 16(4).
- 8) Brenner et al. 2022. CMAJ. 194 (17)

